Posted by Michael Wonder on 01 May 2016

Schedule of Pharmaceutical Benefits - 1 May 2016 update

1 May 2016 - The May 2016 issue of the Schedule sees a number of new and revised listings.

The major new & revised listings are:

  • Bendamustine hydrochloride (Ribomustin) - new listing for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
  • Ombitasvir with paritaprevir and ritonavir and dasabuvir sodium monohydrate (Viekira Pak) - new combination product for hepatitis C
  • Ombitasvir with paritaprevir and ritonavir and dasabuvir sodium monohydrate and ribavirin (Viekira Pak RBV) - new combination product for hepatitis C
  • Nivolumab (Opdivo) - new listing for malignant melanoma
  • Usetekinumab (Stelara) - new indication for psoriatic arthritis

All new and revised PBS listings have been entered into the MAESTrO database.

For more details, go to: http://www.pbs.gov.au/browse/changes

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Combination product , Listing , Australia , Hepatitis C